Methylglyoxal induces hyperpermeability of the blood-retinal barrier via the loss of tight junction proteins and the activation of matrix metalloproteinases

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 5, 2012, Pages 691-697

  Kim, Junghyun ^a   Kim, Chan Sik ^a   Lee, Yun Mi ^a   Jo, Kyuhyung ^a   Shin, So Dam ^a   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Blood retinal barrier; Matrix metalloproteinases; Methylglyoxal; Occludin

Indexed keywords

GELATINASE A; GELATINASE B; METHYLGLYOXAL; OCCLUDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; MALE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; RETINA BLOOD VESSEL;

ANIMALS; BLOOD GLUCOSE; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENZYME ACTIVATION; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INTRAVITREAL INJECTIONS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; PYRUVALDEHYDE; RATS; RATS, SPRAGUE-DAWLEY; RETINAL VESSELS; SERUM ALBUMIN, BOVINE;

EID: 84862903126     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1912-5     Document Type: Article

References (41)

1. Cunha-Vaz J, Bernardes R (2005) Nonproliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Prog Retin Eye Res 24: 355-377
2. Roy S, Sato T, Paryani G, Kao R (2003) Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes 52: 1229-1234
3. Sander B, Larsen M, Engler C, Lund-Andersen H, Parving HH (1994) Early changes in diabetic retinopathy: capillary loss and blood-retina barrier permeability in relation to metabolic control. Acta Ophthalmol 72: 553-559
4. Patz A (1980) Studies on retinal neovascularization. Friedenwald Lecture. Invest Ophthalmol Vis Sci 19: 1133-1138
5. Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 85: 597-607
6. Sander CS, Hamm F, Elsner P, Thiele JJ (2003) Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol 148: 913-922
7. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170
8. Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK, Liu FT, Thorpe SR, Gardiner TA (2005) Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. Diabetes 54: 785-794
9. Hirahara I, Kusano E, Yanagiba S, Miyata Y, Ando Y, Muto S, Asano Y (2006) Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 26: 380-392
10. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T (1999) Induction of 1, 2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heatsterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 19: 325-333
11. Bento CF, Fernandes R, Matafome P, Sena C, Seica R, Pereira P (2010) Methylglyoxal-induced imbalance in the ratio of vascular endothelial growth factor to angiopoietin 2 secreted by retinal pigment epithelial cells leads to endothelial dysfunction. Exp Physiol 95: 955-970
12. Berkowitz BA, Lukaszew RA, Mullins CM, Penn JS (1998) Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 39: 391-396
13. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R (1998) Diabetic retinopathy. Diabetes Care 21: 143-156
14. Randell EW, Vasdev S, Gill V (2005)Measurement of methylglyoxal in rat tissues by electrospray ionization mass spectrometry and liquid chromatography. J Pharmacol Toxicol Methods 51: 153-157
15. Hammes HP (2003) Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complicat 17: 16-19
16. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9: 294-299
17. Akhand AA, Hossain K, Mitsui H, Kato M, Miyata T, Inagi R, Du J, Takeda K, Kawamoto Y, Suzuki H, Kurokawa K, Nakashima I (2001) Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med 31: 20-30
18. Fukunaga M, Miyata S, Liu BF, Miyazaki H, Hirota Y, Higo S, Hamada Y, Ueyama S, Kasuga M (2004) Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. Biochem Biophys Res Commun 320: 689-695
19. Huang WJ, Tung CW, Ho C, Yang JT, ChenML, Chang PJ, Lee PH, Lin CL, Wang JY (2007) Ras activation modulates methylglyoxalinduced mesangial cell apoptosis through superoxide production. Ren Fail 29: 911-921
20. Kim J, Son JW, Lee JA, Oh YS, Shinn SH (2004) Methylglyoxal induces apoptosis mediated by reactive oxygen species in bovine retinal pericytes. J Korean Med Sci 19: 95-100
21. Lapolla A, Flamini R, Dalla Vedova A, Senesi A, Reitano R, Fedele D, Basso E, Seraglia R, Traldi P (2003) Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin Chem Lab Med 41: 1166-1173
22. Lapolla A, Reitano R, Seraglia R, Sartore G, Ragazzi E, Traldi P (2005) Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress. Mol Nutr Food Res 49: 685-690
23. Chaplen FW, Fahl WE, Cameron DC (1998) Evidence of high levels of methylglyoxal in cultured Chinese hamster ovary cells. Proc Natl Acad Sci USA 95: 5533-5538
24. Kim J, Kim OS, Kim CS, Kim NH, Kim JS (2010) Cytotoxic role of methylglyoxal in rat retinal pericytes: Involvement of a nuclear factor-kappaB and inducible nitric oxide synthase pathway. Chem Biol Interact 188: 86-93
25. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS (1996) Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98: 2572-2579
26. Vincenti MP (2001) The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and celltype- specific expression. Methods Mol Biol 151: 121-148
27. Portik-Dobos V, Anstadt MP, Hutchinson J, Bannan M, Ergul A (2002) Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51: 3063-3068
28. Uemura S, Matsushita H, LiW, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS (2001) Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88: 1291-1298
29. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G (1997) Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40: 1449-1454
30. Song RH, Singh AK, Leehey DJ (1999) Decreased glomerular proteinase activity in the streptozotocin diabetic rat. Am J Nephrol 19: 441-446
31. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH (2001) Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21: 7724-7732
32. Alexander JS, Elrod JW (2002) Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 200: 561-574
33. Grant MB, Caballero S, Tarnuzzer RW, Bass KE, Ljubimov AV, Spoerri PE, Galardy RE (1998) Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 47: 1311-1317
34. BehzadianMA, Windsor LJ, Ghaly N, Liou G, Tsai NT, Caldwell RB (2003) VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 17: 752-754
35. Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP (2003) The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 44: 4457-4464
36. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S (1993) Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123: 1777-1788
37. Watson PM, Anderson JM, Vanltallie CM, Doctrow SR (1991) The tight-junction-specific protein ZO-1 is a component of the human and rat blood-brain barriers. Neurosci Lett 129: 6-10
38. Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, Fujimoto K, Tsukita S, Rubin LL (1997) Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 110 (Pt 14): 1603-1613
39. Chen Y, Merzdorf C, Paul DL, Goodenough DA (1997) COOH terminus of occludin is required for tight junction barrier function in early Xenopus embryos. J Cell Biol 138: 891-899
40. Wong V, Gumbiner BM (1997) A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J Cell Biol 136: 399-409
41. LiuW, Hendren J, Qin XJ, Shen J, Liu KJ (2009) Normobaric hyperoxia attenuates early blood-brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem 108: 811-820